Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. LFMD
LFMD logo

LFMD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy LifeMD Inc (LFMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
4.880
1 Day change
-0.61%
52 Week Range
14.610
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

LFMD is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock had a strong daily move, but the technical setup is mixed, there is no fresh news catalyst, no strong proprietary buy signal, and fundamentals are not available enough here to justify an aggressive long-term purchase. If you want immediate action, this is better treated as a hold than a buy.

Technical Analysis

Price closed at 4.865 after a 7.27% regular-session gain, which shows short-term momentum. However, MACD histogram is still negative at -0.0144 and contracting, suggesting the trend has not fully turned bullish yet. RSI_6 at 67.548 is near the upper end of neutral and close to overbought territory, so upside may be limited in the near term. Moving averages are converging, which usually signals indecision rather than a confirmed trend. Key levels: pivot 4.473, resistance 4.931, support 4.014. The stock is trading just below first resistance, so it is not an especially attractive entry for a long-term beginner who is unwilling to wait.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is strongly bullish. Call open interest is 37,199 versus put open interest of 6,996, and the put-call ratios are very low on both open interest (0.19) and volume (0.06), indicating traders are positioning heavily toward upside. Today’s option volume is also elevated versus the 30-day average, which supports active speculation. Implied volatility is high at 88.95, showing the market expects meaningful movement, but not necessarily confirming a durable long-term trend.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
9

Positive Catalysts

  • ["Strong bullish options positioning suggests near-term upside sentiment.", "Recent session price strength shows buyers stepped in aggressively.", "Similar candlestick-pattern analysis suggests possible short-term follow-through, with an estimated 8.45% chance over the next month."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh event-driven catalyst.", "No AI Stock Picker signal today.", "No SwingMax signal recently.", "Hedge funds and insiders are both neutral, with no notable accumulation.", "MACD remains negative, so the technical trend is not fully confirmed.", "No recent congress trading data and no politician/influential figure activity reported."]

Financial Performance

No usable latest-quarter financial snapshot was provided due to an error, so I cannot verify revenue, earnings, or margin trends for the most recent quarter season. Based on the provided data alone, there is not enough financial evidence to support a long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no visible wall street upgrade/downgrade trend to support a stronger bullish case. From the available pros-and-cons view, the pros are decent short-term options sentiment and recent price strength, while the cons are missing catalyst support, neutral insider/hedge fund activity, and no confirmed technical breakout.

Wall Street analysts forecast LFMD stock price to rise
7 Analyst Rating
Wall Street analysts forecast LFMD stock price to rise
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.910
sliders
Low
6
Averages
9.67
High
15
Current: 4.910
sliders
Low
6
Averages
9.67
High
15
Mizuho
Neutral -> Outperform
upgrade
$6 -> $8
AI Analysis
2026-03-16
Reason
Mizuho
Price Target
$6 -> $8
AI Analysis
2026-03-16
upgrade
Neutral -> Outperform
Reason
Mizuho upgraded LifeMD to Outperform from Neutral with a price target of $8, up from $6. The firm cites the company's better than expected 2026 outlook for the upgrade. LifeMD continues to expand into new therapeutic areas for virtual care, but the investment thesis is still riven by the company's weight loss management program, the analyst tells investors in a research note. Mizuho sees the company's oral GLP-1 drugs "serving as the anchor" to drive patient growth in 2026 and beyond. It views LifeMD as a "portfolio" play on branded GLP-1s from both Eli Lilly and Novo Nordisk, "without having to decide which manufacturer will be the winner."
Freedom Capital
Buy
upgrade
$8 -> $10
2026-03-12
Reason
Freedom Capital
Price Target
$8 -> $10
2026-03-12
upgrade
Buy
Reason
Freedom Capital raised the firm's price target on LifeMD to $10 from $8 and keeps a Buy rating on the shares. The company's Q4 reported confirm a growth reacceleration as its revenue and adjusted EBITDA beat expectations, the analyst tells investors in a research note. The firm sees share upside from LifeMD's user-retention metrics.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for LFMD
Unlock Now

People Also Watch